Literature DB >> 18542786

Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum.

Lori A Wood1, Bernard Escudier, Neil Reaume.   

Abstract

The first annual Canadian Genitourinary Medical Oncology Conference was held in June 2006 before the Canadian Urology Association Annual Meeting. This article summarizes 3 presentations that took place as part of the Renal Cell Carcinoma Forum: "Treatment of Metastatic Renal Cell Carcinoma: 2006 and Beyond" was presented by Dr. Bernard Escudier; "Practical Experience with Targeted Therapy," by Dr. Lori Wood; and "Sarcomatoid Renal Cell Carcinoma," by Dr. Neil Reaume.

Entities:  

Year:  2007        PMID： 18542786      PMCID： PMC2422956          DOI： 10.5489/cuaj.62

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  16 in total

1.  Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.

Authors:  Melissa P Upton; Robert A Parker; Amanda Youmans; David F McDermott; Michael B Atkins
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

2.  Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).

Authors:  S Störkel; J N Eble; K Adlakha; M Amin; M L Blute; D G Bostwick; M Darson; B Delahunt; K Iczkowski
Journal:  Cancer       Date:  1997-09-01       Impact factor: 6.860

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3.

Authors:  G M Farrow; E G Harrison; D C Utz
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

5.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

Authors:  Robert J Motzer; Jennifer Bacik; Tania Mariani; Paul Russo; Madhu Mazumdar; Victor Reuter
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

6.  Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

Authors:  T Cangiano; J Liao; J Naitoh; F Dorey; R Figlin; A Belldegrun
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

7.  Sarcomatoid carcinoma of the kidney.

Authors:  F Bertoni; C Ferri; A Benati; P Bacchini; F Corrado
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

8.  Sarcomatoid renal carcinoma.

Authors:  K M Tomera; G M Farrow; M M Lieber
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

9.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Authors:  Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

Authors:  B Escudier; J P Droz; F Rolland; M J Terrier-Lacombe; G Gravis; P Beuzeboc; B Chauvet; C Chevreau; J C Eymard; T Lesimple; Y Merrouche; S Oudard; F Priou; C Guillemare; S Gourgou; S Culine
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.